Press release
IDEXX Empowers Veterinarians with New Testing Insights that Support Earlier Diagnosis and Intervention for Preventive Care and Critical Cases
IDEXX Reference Laboratories Will Add Fecal Dx Antigen Testing with Flea Tapeworm Detection, Testing for the FGF-23 Kidney Biomarker, and Next-Day PCR Direct
About this update from Idexx Laboratories, Inc.
[{"type":"text","content":"IDEXX Reference Laboratories Will Add Fecal Dx Antigen Testing with Flea Tapeworm Detection, Testing for the FGF-23 Kidney Biomarker, and Next-Day PCR Direct Testing Service\nWESTBROOK, Maine, June 21, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces new reference laboratory tests and services to help veterinarians gain insights during wellness screenings, develop treatment plans for cats with chronic kidney disease, and access fast, definitive answers for the most critical cases.\n\n \n \n \n \n \n \n\n \n\"The expansion of our reference laboratory menu demonstrates our continued focus on innovations that create clarity for our veterinary customers, supporting our shared mission to advance the standard of care for pets,\" said Jay Mazelsky, IDEXX President and Chief Executive Officer. \"The new offerings add to the unmatched customer experience at IDEXX Reference Laboratories, which includes access to specialists who offer personalized guidance, as an extension of the practice.\"\nStarting in September 2022, customers of IDEXX Reference Laboratories in North America will benefit from the following new tests and services:\nFecal Dx® antigen testing is expanded to include the detection of flea tapeworm in addition to current tests for hookworm, roundworm, and whipworm. Flea tapeworm is a common intestinal parasite that is transmitted anywhere fleas are found, and it may often remain undetected by testing methods like fecal flotation or other instrument-based optical methods that rely on the presence of eggs. With this addition, Fecal Dx antigen testing detects up to five times more of these common intestinal parasites, and earlier, than fecal flotation alone.1 This provides veterinarians with valuable insights as part of annual wellness screens and allows them to have more confident conversations with pet owners around treatment and prevention, supporting better patient outcomes.A first in North America, IDEXX is enhancing its suite of kidney health diagnostics with the addition of FGF-23, a kidney disease management biomarker. IDEXX FGF-23 provides quantifiable, evidence-based insights for veterinarians caring for cats with early chronic kidney disease (CKD),* enabling more confident treatment recommendations, such as dietary change. With IDEXX FGF-23 in additi...